Latest Breaking News On - Advanced lung disease program - Page 1 : comparemela.com

United Therapeutics Announces New England Journal of Medicine Publication of the INCREASE Study Evaluating Tyvaso® in Pulmonary Hypertension Associated with Interstitial Lung Disease INCREASE Study is First to Demonstrate a Clear Benefit in Patients with PH-ILD, a Life-threatening Disease with No Currently FDA-Approved Treatments Company to host a webcast detailing the INCREASE study results on Tuesday, January 19, 2021 at 4:30 p.m. E.T. News provided by Share this article Share this article SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 13, 2021 /PRNewswire/  United Therapeutics Corporation (Nasdaq: UTHR) today announced that results from the INCREASE clinical study of Tyvaso ® (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) have been published online in the

Leigh petersonStevend nathanMichael benkowitzDewey steadmanLung disease programUnited therapeutics corporationSteering committeeWorld health organizationProfessor of medicine at virginia commonwealth universityUnited therapeutics corporation nasdaqExchange commissionProduct development at united therapeuticsInhalation solutionNew england journalAdvanced lung disease programLung transplant program